LOS ANGELES, CALIFORNIA--(Marketwired - April 30, 2015) - Convalo Health International, Corp. (Convalo) (TSX VENTURE:CXV), a company focused on rolling up the highly-fragmented addiction recovery sector of companies in the US, provided highlights of its financial results for Q1 FY 2015 on a conference call earlier today.
To listen to the full interactive conference call, please go to the link provided:
https://cc.readytalk.com/play?id=6m0bbo
Participants from Convalo were Michael Dalsin (Chairman) and David Ward (CFO).
About Convalo
Convalo is an acquisition-oriented company focused on rolling up the US outpatient addiction rehabilitation market led by seasoned management with experience in both US healthcare acquisitions and healthcare service asset management. In 2014, Convalo made its first acquisition of a small, local addiction rehabilitation center in Los Angeles. That business has operated under the brand name BLVD Centers (www.blvdcenters.com) in a luxury Hollywood, California location. BLVD offers patients access to a wide range of services, including addictive and co-occurring disorders, helpful to the recovery process. In conjunction with the 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Convalo and anticipated events or results, are assumptions based on beliefs of Convalo's senior management as well as information currently available to it. While these assumptions were considered reasonable by Convalo at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected. This press release refers non-GAAP and non-IFRS financial measures that do not have standardized meaning prescribed by GAAP or IFRS. Convalo's presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These financial measures are intended to provide additional information to investors concerning Convalo's performance.
Contact Information:
Dennis Wilson
Corporate Affairs
investorinfo@convalohealth.com
www.convalohealth.com